Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristen Speaker

Developmental - Behavioral Pediatrics Lincoln, NE Nurse Practitioner

NPI 1861912453 CMS profile 3185906

8101 O St Ste 112, Lincoln, NE 68510

Open in the dashboard

General payments

$3,196

206 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Speaker of Lincoln, NE is reported in the CMS Open Payments database as having received $3,196 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Developmental - Behavioral Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 3
2024 General $402 18
2023 General $1,028 59
2022 General $1,199 85
2021 General $521 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Speaker
  • Developmental - Behavioral Pediatrics median
  • Middle half of Developmental - Behavioral Pediatrics
  • National median

In program year 2025, general payments to Kristen Speaker were reported at $47. Among 160 Developmental - Behavioral Pediatrics profiles paid that year, the median was $77 and the middle half received between $27 and $211.

Show as a table
Year Kristen Speaker Developmental - Behavioral Pediatrics median Middle half National median
2019 $0 $106 $28–$315 $163
2020 $0 $55 $19–$181 $114
2021 $521 $96 $25–$343 $132
2022 $1,199 $86 $23–$235 $149
2023 $1,028 $71 $25–$348 $160
2024 $402 $74 $25–$237 $164
2025 $47 $77 $27–$211 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $663 38 payments
  2. Supernus Pharmaceuticals, Inc. $655 37 payments
  3. Alkermes, Inc. $468 51 payments
  4. ITI, Inc. $324 17 payments
  5. Otsuka America Pharmaceutical, Inc. $241 12 payments
  6. Jazz Pharmaceuticals Inc. $121 7 payments
  7. Ironshore Pharmaceuticals Inc. $95 6 payments
  8. Tris Pharma Inc $75 4 payments
  9. Teva Pharmaceuticals USA, Inc. $72 4 payments
  10. Corium, Inc. $66 4 payments
  11. Other $416 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,196 206 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $610 35 payments
  2. QELBREE $561 33 payments
  3. ARISTADA Cns $468 51 payments
  4. ARISTADA Cns $468 51 payments
  5. LYBALVI Cns $384 40 payments
  6. ARISTADA INITIO $368 45 payments
  7. CAPLYTA $324 17 payments
  8. LYBALVI Cns $285 34 payments
  9. ARISTADA Cns $183 17 payments
  10. ARISTADA Cns $183 17 payments
  11. Other $1,447 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

22

Median for Nurse Practitioner: 389

Drug cost

$261

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trazodone Hcl Generic 11 $157
Clonidine Hcl Generic 11 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $94
$94 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $47
$47 — —
CAPLYTA
  • ITI, Inc. $43
$43 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $39
$39 — —
VRAYLAR
  • AbbVie, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Developmental - Behavioral Pediatrics in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record